Zevra Therapeutics, Inc. (ZVRA) Tops Q3 EPS by 14c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q3 EPS of $0.19, $0.14 better than the analyst estimate of $0.05. Revenue for the quarter came in at $34.1 million versus the consensus estimate of $28.05 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Hafnia Limited (HAFN) Tops Q2 EPS by 1c
• Electra Therapeutics files for proposed IPO